Core Viewpoint - TCE's efficacy and commercialization capabilities in hematological malignancies have been fully validated, but several challenges remain for its widespread application in solid tumors [1] Group 1: Current Status of TCE - A total of 12 TCE therapies have been approved globally, with 10 in the US and 6 in China; 9 are for hematological malignancies and only 3 for solid tumors [1] - The application of TCE in solid tumors faces challenges such as targeting tumor-associated antigens (TAA) without harming healthy tissues, enhancing T cell infiltration in the tumor microenvironment, and overcoming immunosuppressive cells and cytokines that lead to T cell exhaustion [1] Group 2: Design Innovations Enhancing TCE Applicability - Non-full-length bispecific antibodies and 2+1 format designs have shown promise; Amgen's DLL3/CD3 bispecific antibody has been approved for SCLC, and MSD's Gocatamig has demonstrated high tumor response rates in later-line SCLC patients [2] - The "2+1" format design allows for precise control of CD3 affinity, with Xencor's XmAb platform advancing its pipeline to Phase III clinical trials [2] - TCR therapy, exemplified by Immunocore's KIMMTRAK, targets intracellular protein antigens and has received FDA approval for uveal melanoma, with potential for expansion into other indications [2] Group 3: Strategies to Mitigate Toxicity and Enhance Efficacy - Prodrug designs are being explored to reduce off-target toxicity; Janux has validated its TCE in clinical settings, and Vir's VIR-5818 shows promising initial data in HER2-positive breast cancer [3] - Co-stimulatory signals from CD28, 4-1BB, and CD2 are expected to enhance TCE responses; Regeneron's CD28 bispecific antibody strategy has shown effectiveness but raised safety concerns [3] - Selective T cell activation targets are being developed to avoid broad T cell activation risks; AstraZeneca and LavaTherapeutics are working on TCEs that selectively target CD8+ T cells and Vγ9Vδ2 T cells [4] Group 4: Domestic Companies and Pipeline Development - Domestic companies are advancing TCE research with diverse technical paths, including CD28 co-stimulatory bispecific antibodies and TCR therapies, forming a robust pipeline [5] - Companies to watch include Zai Lab, Wuxi Biologics, Heng Rui Medicine, Bai Li Tianheng, and others, indicating a rich landscape for TCE development in solid tumors [5]

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have issued the updated National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the Commercial Health Insurance Innovative Drug Catalog for 2025, which includes 114 new drugs, 50 of which are Class 1 innovative drugs [1][2] Group 1: Drug Catalog Updates - The 2025 National Medical Insurance Drug Catalog will include drugs that fill gaps in basic insurance coverage, such as treatments for triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as rare diseases like Langerhans cell histiocytosis and thalassemia [1] - The total number of drugs in the updated catalog will increase to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, significantly enhancing coverage for key areas such as oncology, chronic diseases, mental health, rare diseases, and pediatric medications [1] Group 2: Innovation and Policy Support - The 2025 adjustment marks the eighth update since the establishment of the National Healthcare Security Administration, establishing a regular, standardized, and scientific adjustment mechanism aimed at "filling gaps, encouraging innovation, and optimizing structure" [2] - The new Commercial Health Insurance Innovative Drug Catalog includes 19 drugs from 18 innovative pharmaceutical companies, focusing on high innovation, significant clinical value, and patient benefits that exceed basic insurance coverage [2][3] Group 3: Characteristics of the Innovative Drug Catalog - The Commercial Health Insurance Innovative Drug Catalog emphasizes support for innovation, featuring drugs that represent significant advancements in medical technology, including CAR-T, TCE therapies, and bispecific antibodies [3] - It addresses key areas of concern, including drugs for Alzheimer's disease, which aligns with the aging population trend, and treatments for rare diseases prevalent in children, such as Gaucher disease and neuroblastoma [3] - The catalog delineates the boundary between basic medical insurance and commercial insurance, with basic insurance focusing on safe, effective, and mature-target mechanism drugs, while commercial insurance emphasizes innovative and cutting-edge medications [3]

Core Viewpoint - Shimai Pharmaceutical has submitted an application to the Hong Kong Stock Exchange for its main board listing, with Huatai International acting as the sole sponsor [1] Industry Summary - The T-cell engaging (TCE) therapy market is projected to grow significantly, from $3 billion in 2024 to $121.1 billion by 2035, representing a compound annual growth rate (CAGR) of 40.0% [1] Company Summary - As of November 5, 2025, Shimai Pharmaceutical has four self-developed clinical-stage candidate drugs, including DNV3 targeting LAG3, SMET12 for intravenous use targeting EGFR×CD3, CMD011 targeting GPC3×CD3, and the next-generation cloaked TCE CMDE005 [1] - The company is also developing two preclinical next-generation multifunctional/logic-gated TCE candidates, CMDE101 and CMDE102, targeting FOLR1×PD-L1×CD3 and PSMA×PD-L1×CD3, respectively [1] - Shimai Pharmaceutical emphasizes that its TCE therapies feature selective activation, zero immune cell toxicity, precise tumor recognition, and prevention of tumor recurrence, aiming to become a cornerstone therapy in future tumor immunotherapy [1]

Investment Rating - The report maintains a "Buy" recommendation for the industry [3] Core Insights - The report highlights the urgent need for innovative therapies in the treatment of systemic lupus erythematosus (SLE), a condition with a significant patient burden and no current curative treatment options [7][19][21] - B cell-targeted therapies, particularly myeloid cell engagers (MCE), are emerging as promising solutions for SLE, with the potential to achieve deep and lasting depletion of pathogenic B cells [9][10][19] - The report emphasizes the clinical progress of companies like Yiming Oncology, Sanofi, Dren Bio, and LTZ Therapeutics, which are leading in the development of MCE therapies [10][19] Summary by Sections B Cell Autoimmune Diseases - Autoimmune diseases are characterized by the immune system mistakenly attacking the body's own tissues, with a wide variety of B cell autoimmune diseases affecting millions globally, including rheumatoid arthritis (39.8 million), systemic lupus erythematosus (7.8 million), and multiple sclerosis (2.8 million) [13][14] SLE: Patient Population and Disease Burden - SLE is a complex autoimmune disease affecting multiple systems and organs, with a significant prevalence in women aged 20-40, leading to severe health impacts and a strong desire for effective treatments [17][18] SLE Treatment: Unmet Clinical Needs - Current treatments for SLE are inadequate, with a low long-term remission rate and high recurrence risk, highlighting the need for innovative therapies that can provide sustained relief and potentially cure the disease [19][20][21] T Cell-Based Therapies: CAR-T and TCE - CAR-T and T cell engagers (TCE) are being explored for their ability to target and deplete pathogenic B cells, with CAR-T showing promising long-term efficacy in SLE patients [24][37] - However, CAR-T therapies are expensive and complex, while TCEs offer a more standardized and potentially safer alternative, though they may not achieve the same depth of B cell depletion [41][43] Myeloid Cell Engagers (MCE) - MCE therapies represent a novel approach by utilizing myeloid cells to target and eliminate pathogenic B cells, with initial clinical data suggesting promising safety and efficacy profiles [9][10][46] - Companies like Yiming Oncology are at the forefront of this innovation, with upcoming clinical data expected to provide further insights into the effectiveness of MCE therapies for SLE [10][19]